Can I read GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG‐1401 on EtoBox?

GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG‐1401 by Akira Yokomizo; Masaki Shiota; Futoshi Morokuma; Masatoshi Eto; Hideyasu Matsuyama; Hiroaki Matsumoto; Toshiyuki Kamoto; Naoki Terada; Kazuya Kawahara; Hideki Enokida; Shuichi Tatarano; Naohiro Fujimoto; Katsuyoshi Higasijima; Hideki Sakai; Tomoaki Hakariya; Tsukasa Igawa; Shigetaka Suekane; Tomomi Kamba; Yutaka Sugiyama; Junji Kishimoto; Seiji Naito is a Medicine article available to read on EtoBox.

What is GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG‐1401 about?

## Objectives To compare the effectiveness and safety of gonadotropin‐releasing hormone (GnRH) antagonist monotherapy to combined androgen blockade (CAB) with a GnRH agonist and bicalutamide in patients with advanced hormone‐sensitive prostate cancer (HSPC). ## Methods The study was conducted as KYUCOG‐1401 trial (UMIN000014243) and enrolled 200 patients who were randomly assigned to either group A (GnRH antagonist monotherapy followed by the addition of bicalutamide) or group B (CAB by a GnRH agonist and bicalutamide). The primary endpoint was PSA progression‐free survival. The secondary endpoints were the time to CAB treatment failure, radiographic progression‐free survival, overall survival, changes in serum parameters, including PSA, hormones, and bone and lipid metabolic markers, and adverse events. ## Results PSA progression‐free survival was significantly longer in group B (hazard ratio [HR], 95% confidence interval [CI]; 1.40, 1.01–1.95, __p__ = 0.041). The time to CAB treatment failure was slightly longer in group A (HR, 95% CI; 0.80, 0.59–1.08, __p__ = 0.146). No significant differences were observed in radiographic progression‐free survival or overall survival. The perce

Who reads GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone‐sensitive prostate cancer; KYUCOG‐1401?

Author

Akira Yokomizo; Masaki Shiota; Futoshi Morokuma; Masatoshi Eto; Hideyasu Matsuyama; Hiroaki Matsumoto; Toshiyuki Kamoto; Naoki Terada; Kazuya Kawahara; Hideki Enokida; Shuichi Tatarano; Naohiro Fujimoto; Katsuyoshi Higasijima; Hideki Sakai; Tomoaki Hakariya; Tsukasa Igawa; Shigetaka Suekane; Tomomi Kamba; Yutaka Sugiyama; Junji Kishimoto; Seiji Naito

Publisher

Wiley

Published

2023

Language

EN

Field

Medicine (Health Sciences)